Cargando…

Targeting necroptosis in muscle fibers ameliorates inflammatory myopathies

Muscle cell death in polymyositis is induced by CD8(+) cytotoxic T lymphocytes. We hypothesized that the injured muscle fibers release pro-inflammatory molecules, which would further accelerate CD8(+) cytotoxic T lymphocytes-induced muscle injury, and inhibition of the cell death of muscle fibers co...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamiya, Mari, Mizoguchi, Fumitaka, Kawahata, Kimito, Wang, Dengli, Nishibori, Masahiro, Day, Jessica, Louis, Cynthia, Wicks, Ian P., Kohsaka, Hitoshi, Yasuda, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748624/
https://www.ncbi.nlm.nih.gov/pubmed/35013338
http://dx.doi.org/10.1038/s41467-021-27875-4
Descripción
Sumario:Muscle cell death in polymyositis is induced by CD8(+) cytotoxic T lymphocytes. We hypothesized that the injured muscle fibers release pro-inflammatory molecules, which would further accelerate CD8(+) cytotoxic T lymphocytes-induced muscle injury, and inhibition of the cell death of muscle fibers could be a novel therapeutic strategy to suppress both muscle injury and inflammation in polymyositis. Here, we show that the pattern of cell death of muscle fibers in polymyositis is FAS ligand-dependent necroptosis, while that of satellite cells and myoblasts is perforin 1/granzyme B-dependent apoptosis, using human muscle biopsy specimens of polymyositis patients and models of polymyositis in vitro and in vivo. Inhibition of necroptosis suppresses not only CD8(+) cytotoxic T lymphocytes-induced cell death of myotubes but also the release of inflammatory molecules including HMGB1. Treatment with a necroptosis inhibitor or anti-HMGB1 antibodies ameliorates myositis-induced muscle weakness as well as muscle cell death and inflammation in the muscles. Thus, targeting necroptosis in muscle cells is a promising strategy for treating polymyositis providing an alternative to current therapies directed at leukocytes.